Introduction: Erectile dysfunction (ED) after cavernous nerve (CN) injury remains difficult to treat. Calpain plays a critical role in causing neurodegenerative diseases. This study aimed to evaluate whether calpain inhibition preserves erectile function in a rat model of CN injury. Materials and Methods: Rats underwent sham surgery or CN crush injury. The CN-crushed rats were treated with vehicle or MDL-28170, a specific calpain inhibitor. At 1, 2, 3, and 7 days post-surgery, major pelvic ganglia (MPG) were harvested, followed by the measurement of erectile function, respectively. At 28 days, penile tissue and distal CN were harvested, followed by the measurement of erectile function in rats. Calpain activity in MPG and corpus cavernosum, as well as TGF-β1/Smad2 and collagen content in corpus cavernosum, were measured by western blot. Neuronal nitric oxide synthase (nNOS) was observed by immunohistochemistry. Results: Increased calpain activity was observed in MPG and corpus cavernosum. CN crush markedly attenuated the erectile responses and nNOS expression in CN, and these were improved by MDL-28170 treatment. Furthermore, treatment prevented increased TGF-β1/Smad2 and collagen expression in corpus cavernosum. Conclusions: Our results suggested that calpain activation plays a role in pathogenesis of CN injury-associated ED. Calpain inhibition could be a novel approach for preventing the development of ED following CN injury.

Keywords:
Calpain, Cavernous nerve injury, Erectile dysfunction, Fibrosis, Neuroprotection
1.
Walz J, Burnett AL, Costello AJ, et al: A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy. Eur Urol 2010;57:179-192.
2.
Ludwig W, Phillips M: Organic causes of erectile dysfunction in men under 40. Urol Int 2014;92:1-6.
3.
Mulhall JP, Graydon RJ: The hemodynamics of erectile dysfunction following nerve-sparing radical retropubic prostatectomy. Int J Impot Res 1996;8:91-94.
4.
Burnett AL: Erectile dysfunction following radical prostatectomy. JAMA 2005;293:2648-2653.
5.
Burnett AL, Allaf ME, Bivalacqua TJ: Erythropoietin promotes erection recovery after nerve-sparing radical retropubic prostatectomy: a retrospective analysis. J Sex Med 2008;5:2392-2398.
6.
Zhang XM, Shi PH, Cao SH, et al: Expression changes of transforming growth factor-beta1 and thrombospondin-1 in cavernous tissues of diabetic rats. Urol Int 2010;84:221-225.
7.
Shin TY, Ryu JK, Jin HR, et al: Increased cavernous expression of transforming growth factor-β1 and activation of the Smad signaling pathway affects erectile dysfunction in men with spinal cord injury. J Sex Med 2011;8:1454-1462.
8.
Li H, He WY, Lin F, et al: Panax notoginseng saponins improve erectile function through attenuation of oxidative stress, restoration of Akt activity and protection of endothelial and smooth muscle cells in diabetic rats with erectile dysfunction. Urol Int 2014;93:92-99.
9.
Zhou F, Li GY, Gao ZZ, et al: The TGF-β1/Smad/CTGF pathway and corpus cavernosum fibrous-muscular alterations in rats with streptozotocin-induced diabetes. J Androl 2012;33:651-659.
10.
Donkor IO: Calpain inhibitors: a survey of compounds reported in the patent and scientific literature. Expert Opin Ther Pat 2011;21:601-636.
11.
Suzuki K, Hata S, Kawabata Y, Sorimachi H: Structure, activation, and biology of calpain. Diabetes 2004;53(suppl 1):S12-S18.
12.
Franco SJ, Huttenlocher A: Regulating cell migration: calpains make the cut. J Cell Sci 2005;118:3829-3838.
13.
Qiu K, Su Y, Block ER: Use of recombinant calpain-2 siRNA adenovirus to assess calpain-2 modulation of lung endothelial cell migration and proliferation. Mol Cell Biochem 2006;292:69-78.
14.
Huang Y, Wang KK: The calpain family and human disease. Trends Mol Med 2001;7:355-362.
15.
Araújo Couto L, Sampaio Narciso M, Hokoç JN, Blanco Martinez AM: Calpain inhibitor 2 prevents axonal degeneration of opossum optic nerve fibers. J Neurosci Res 2004;77:410-419.
16.
Narayan RK, Michel ME, Ansell B, et al: Clinical trials in head injury. Neurotrauma 2002;19:503-557.
17.
McGinn MJ, Kelley BJ, Akinyi L, et al: Biochemical, structural, and biomarker evidence for calpain-mediated cytoskeletal change after diffuse brain injury uncomplicated by contusion. J Neuropathol Exp Neurol 2009;68:241-249.
18.
Agudo M, Pérez-Marín MC, Sobrado-Calvo P, et al: Immediate upregulation of proteins belonging to different branches of the apoptotic cascade in the retina after optic nerve transection and optic nerve crush. Invest Ophthalmol Vis Sci 2009;50:424-431.
19.
Schafer DP, Jha S, Liu F, Akella T, McCullough LD, Rasband MN: Disruption of the axon initial segment cytoskeleton is a new mechanism for neuronal injury. J Neurosci 2009;29:13242-13254.
20.
Ma W, Han W, Greer PA, et al: Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. J Clin Invest 2011;121:4548-4566.
21.
Mehdi S: Cell-penetrating inhibitors of calpain. Trends Biochem Sci 1991;16:150-153.
22.
Ryu M, Yasuda M, Shi D, et al: Critical role of calpain in axonal damage-induced retinal ganglion cell death. J Neurosci Res 2012;90:802-815.
23.
Nozaki K, Das A, Ray SK, Banik NL: Calpain inhibition attenuates intracellular changes in muscle cells in response to extracellular inflammatory stimulation. Exp Neurol 2010;225:430-435.
24.
Wang CH, Chen YJ, Lee TH, et al: Protective effect of MDL28170 against thioacetamide-induced acute liver failure in mice. J Biomed Sci 2004;11:571-578.
25.
Albersen M, Fandel TM, Lin G, et al: Injections of adipose tissue-derived stem cells and stem cell lysate improve recovery of erectile function in a rat model of cavernous nerve injury. J Sex Med 2010;7:3331-3340.
26.
Wan ZH, Li WZ, Li YZ, et al: Poly(ADP-Ribose) Polymerase Inhibition Improves Erectile Function in Diabetic Rats. J Sex Med 2011;8:1002-1014.
27.
Lagoda G, Jin L, Lehrfeld TJ, Liu T, Burnett AL: FK506 and sildenafil promote erectile function recovery after cavernous nerve injury through antioxidative mechanisms. J Sex Med 2007;4:908-916.
28.
Fandel TM, Bella AJ, Lin G, et al: Intracavernous growth differentiation factor-5 therapy enhances the recovery of erectile function in a rat model of cavernous nerve injury. J Sex Med 2008;5:1866-1875.
29.
Vanderklish PW, Bahr BA: The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. Int J Exp Pathol 2000;81:323-339.
30.
Gressner OA, Lahme B, Siluschek M, et al: Activation of TGF-beta within cultured hepatocytes and in liver injury leads to intracrine signaling with expression of connective tissue growth factor. J Cell Mol Med 2008;12:2717-2730.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.